Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients

Overview

Journal Biol Blood Marrow Transplant

Date 2018 Apr 16

PMID 29656138

Citations 5

Authors

Jeannine S McCune

Barry Storer

Sushma Thomas

Jozefa McKiernan

Rohan Gupta

Brenda M Sandmaier

Affiliations

Soon will be listed here.

Abstract

We evaluated inosine monophosphate dehydrogenase (IMPDH) 1 and IMPDH2 pharmacogenetics in 247 recipient-donor pairs after nonmyeloablative hematopoietic cell transplant (HCT). Patients were conditioned with total body irradiation + fludarabine and received grafts from related or unrelated donors (10% HLA mismatch), with postgraft immunosuppression of mycophenolate mofetil (MMF) with a calcineurin inhibitor. Recipient and donor IMPDH genotypes (rs11706052, rs2278294, rs2278293) were not associated with day 28 T cell chimerism, acute graft-versus-host disease (GVHD), disease relapse, cytomegalovirus reactivation, nonrelapse mortality, or overall survival. Recipient IMPDH1 rs2278293 genotype was associated with a lower incidence of chronic GVHD (hazard ratio, .72; P = .008) in nonmyeloablative HCT recipients. Additional studies are needed to confirm these results with the goal of identifying predictive biomarkers to MMF that lower GVHD.

Citing Articles

An Exploratory Study of the Metabolite Profiling from Pesticides Exposed Workers.

Nolasco D, Mendes M, Marciano L, Costa L, Macedo A, Sakakibara I Metabolites. 2023; 13(5).

PMID: 37233637 PMC: 10220970. DOI: 10.3390/metabo13050596.

Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.

Partanen J, Hyvarinen K, Bickeboller H, Bogunia-Kubik K, Crossland R, Ivanova M Front Immunol. 2020; 11:575492.

PMID: 33193367 PMC: 7604383. DOI: 10.3389/fimmu.2020.575492.

Disease Progression in Patients with Autosomal Dominant Retinitis Pigmentosa due to a Mutation in Inosine Monophosphate Dehydrogenase 1 (IMPDH1).

Bennett L, Klein M, John F, Radojevic B, Jones K, Birch D Transl Vis Sci Technol. 2020; 9(5):14.

PMID: 32821486 PMC: 7401855. DOI: 10.1167/tvst.9.5.14.

Interindividual Variability in Lymphocyte Stimulation and Transcriptomic Response Predicts Mycophenolic Acid Sensitivity in Healthy Volunteers.

Collins K, Cheng Y, Ferreira R, Gao H, Dollins M, Janosevic D Clin Transl Sci. 2020; 13(6):1137-1149.

PMID: 32415749 PMC: 7719379. DOI: 10.1111/cts.12795.

Drug monitoring for mycophenolic acid in graft-vs-host disease prophylaxis in cord blood transplantation.

Muranushi H, Kanda J, Arai Y, Shindo T, Hishizawa M, Yamamoto T Br J Clin Pharmacol. 2020; 86(12):2464-2472.

PMID: 32386102 PMC: 7688537. DOI: 10.1111/bcp.14354.

References

van Gelder T, Hesselink D, Van Hest R, Mathot R, Van Schaik R . Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?. Ther Drug Monit. 2004; 26(4):343-6. DOI: 10.1097/00007691-200408000-00001. View

Roberts R, Gearry R, Barclay M, Kennedy M . IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J. 2006; 7(5):312-7. DOI: 10.1038/sj.tpj.6500421. View

McSweeney P, Niederwieser D, Shizuru J, Sandmaier B, Molina A, Maloney D . Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001; 97(11):3390-400. DOI: 10.1182/blood.v97.11.3390. View

Van Hest R, Mathot R, Pescovitz M, Gordon R, Mamelok R, van Gelder T . Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients. J Am Soc Nephrol. 2006; 17(3):871-80. DOI: 10.1681/ASN.2005101070. View

Dickinson A, Holler E . Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract Res Clin Haematol. 2008; 21(2):149-64. DOI: 10.1016/j.beha.2008.03.004. View

Glucksberg H, Storb R, Fefer A, Buckner C, Neiman P, Clift R . Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304. DOI: 10.1097/00007890-197410000-00001. View

Kofler S, Shvets N, Bigdeli A, Konig M, Kaczmarek P, Deutsch M . Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study. Am J Transplant. 2009; 9(7):1650-6. DOI: 10.1111/j.1600-6143.2009.02682.x. View

Oetting W, Schladt D, Leduc R, Jacobson P, Guan W, Matas A . Validation of single nucleotide polymorphisms associated with acute rejection in kidney transplant recipients using a large multi-center cohort. Transpl Int. 2011; 24(12):1231-8. PMC: 3208796. DOI: 10.1111/j.1432-2277.2011.01359.x. View

Staatz C, Tett S . Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007; 46(1):13-58. DOI: 10.2165/00003088-200746010-00002. View

10.

Ciftci H, Karadeniz M, Tefik T, Caliskan Y, Yazici H, Demir E . Influence of Proton Pump Inhibitors on Mycophenolic Acid Pharmacokinetics in Patients With Renal Transplantation and the Relationship With Cytochrome 2C19 Gene Polymorphism. Transplant Proc. 2017; 49(3):490-496. DOI: 10.1016/j.transproceed.2017.01.029. View

11.

McDermott C, Sandmaier B, Storer B, Li H, Mager D, Boeckh M . Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013; 19(8):1159-66. PMC: 3720781. DOI: 10.1016/j.bbmt.2013.04.026. View

12.

Baron F, Baker J, Storb R, Gooley T, Sandmaier B, Maris M . Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood. 2004; 104(8):2254-62. DOI: 10.1182/blood-2004-04-1506. View

13.

Laverdiere I, Caron P, Couture F, Guillemette C, Levesque E . Liquid chromatography-coupled tandem mass spectrometry based assay to evaluate inosine-5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells from stem cell transplant recipients. Anal Chem. 2011; 84(1):216-23. DOI: 10.1021/ac202404y. View

14.

Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V . An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2009; 16(3):333-43. DOI: 10.1016/j.bbmt.2009.10.007. View

15.

Nash R, Johnston L, Parker P, McCune J, Storer B, Slattery J . A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005; 11(7):495-505. DOI: 10.1016/j.bbmt.2005.03.006. View

16.

Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y . Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 18(2):273-9. DOI: 10.1016/j.bbmt.2011.06.014. View

17.

Jacobson P, Huang J, Wu J, Kim M, Logan B, Alousi A . Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2009; 16(3):421-9. PMC: 3104501. DOI: 10.1016/j.bbmt.2009.11.010. View

18.

Maris M, Niederwieser D, Sandmaier B, Storer B, Stuart M, Maloney D . HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003; 102(6):2021-30. DOI: 10.1182/blood-2003-02-0482. View

19.

Jaklic A, Collins C, Mrhar A, Sorror M, Sandmaier B, Bemer M . High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients. Int J Clin Pharmacol Ther. 2013; 51(9):711-7. PMC: 3758456. DOI: 10.5414/CP201884. View

20.

Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A . Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001; 15(3):176-84. DOI: 10.1034/j.1399-0012.2001.150306.x. View